Literature DB >> 12662440

Rapid, large-scale generation of highly pure cytomegalovirus-specific cytotoxic T cells for adoptive immunotherapy.

Aaron E Foster1, David J Gottlieb, Marina Marangolo, Anna Bartlett, Yi-Chiao Li, Geoffrey W Barton, Jose A Romagnoli, Kenneth F Bradstock.   

Abstract

Adoptive transfer of donor-derived cytomegalovirus (CMV)-specific cytotoxic T cell (CTL) clones can restore immunity in allogeneic stem cell transplant recipients, providing protection against CMV disease. Current methods for selecting and expanding CMV-specific T cell clones are technically difficult, making adoptive T cell therapy impractical for routine clinical use. In this study, we describe a method for ex vivo generation and expansion of high-purity CMV-specific CTL using peptide-pulsed dendritic cells as antigen-presenting cells. Generation of CMV-specific CTL in numbers sufficient for clinical use in the time span of 4 weeks was accomplished in 6 of 8 CMV-seropositive donors. Examination of pp65 specificity by HLA/peptide tetramer staining demonstrated that a purity of greater than 95% peptide-specific cells could be obtained after two weekly stimulations and retained after further expansion for 3-4 weeks. Median expansion of total cell number was greater than 500-fold and expansion of peptide-specific CTL by tetramer staining was greater than 1.7 x 10(5)-fold. Four weeks after initiating CTL culture, we were able to generate greater than 10(9) total cells that specifically lysed target cells loaded with CMV peptide and cells infected with CMV. This simple and rapid method for generating high-purity CMV-specific CTL for adoptive immunotherapy is currently being examined for routine clinical use for allogeneic stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12662440     DOI: 10.1089/152581603321210172

Source DB:  PubMed          Journal:  J Hematother Stem Cell Res        ISSN: 1525-8165


  5 in total

1.  Targeting cytomegalovirus-infected cells using T cells armed with anti-CD3 × anti-CMV bispecific antibody.

Authors:  Lawrence G Lum; Mayur Ramesh; Archana Thakur; Subhashis Mitra; Abhinav Deol; Joseph P Uberti; Philip E Pellett
Journal:  Biol Blood Marrow Transplant       Date:  2012-02-05       Impact factor: 5.742

Review 2.  The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease.

Authors:  Amy B Hont; Allison B Powell; Danielle K Sohai; Izabella K Valdez; Maja Stanojevic; Ashley E Geiger; Kajal Chaudhary; Ehsan Dowlati; Catherine M Bollard; Conrad Russell Y Cruz
Journal:  Mol Ther       Date:  2022-02-09       Impact factor: 12.910

3.  Development of a serum-free medium for in vitro expansion of human cytotoxic T lymphocytes using a statistical design.

Authors:  Min Kyoung Jeon; Jong-Baeck Lim; Gyun Min Lee
Journal:  BMC Biotechnol       Date:  2010-09-21       Impact factor: 2.563

4.  The early kinetics of cytomegalovirus-specific CD8+ T-cell responses are not affected by antigen load or the absence of perforin or gamma interferon.

Authors:  Daniel M Andrews; Christopher E Andoniou; Peter Fleming; Mark J Smyth; Mariapia A Degli-Esposti
Journal:  J Virol       Date:  2008-03-12       Impact factor: 5.103

Review 5.  Cytomegalovirus Infections in Children with Primary and Secondary Immune Deficiencies.

Authors:  Caroline M Bateman; Alison Kesson; Madeleine Powys; Melanie Wong; Emily Blyth
Journal:  Viruses       Date:  2021-10-05       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.